[1–5] Examples include BRAF inhibitors in melanoma harboring BRAF mutations, ABL kinase inhibitors in chronic myelogenous leukemia with BCR-ABL fusion, EGFR tyrosine kinase inhibitors in non-small cell lung cancer (NSCLC) with an EGFR mutation, and others. The gene discussed is BRAF; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.